Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalbán, Xavier; L. Hauser, Stephen; Kappos, Ludwig; L. Arnold, Douglas; Bar‐Or, Amit; Comi, Giancarlo; Sèze, de; Giovannoni, Gavin; Hartung, Hans‐Peter; Hemmer, Bernhard; Lublin, Fred; Rammohan, Kottil; Selmaj, Krzysztof; Traboulsee, Anthony; Sauter, Annette; Masterman, Donna; Fontoura, Paulo; Belachew, Shibeshih; Garren, Hideki; Mairon, Nicole; Chin, Peter; S. Wolinsky, Jerry

doi:10.1056/nejmoa1606468

Public

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Published in New England Journal of Medicine • Dec 21, 2016

Authors:

Xavier Montalbán

Stephen L. Hauser

Ludwig Kappos

Abstract

BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disea...

Subject

Ocrelizumab

Multiple sclerosis

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!